Dr. Amy Goldstein provides an update on the Mitochondrial Medicine Society.
Areas of discussion include:
Centers of Excellence and the need for community involvement/input
Dr. Amy Goldstein, a member of the Board of Trustees of UMDF, is on faculty at Children’s Hospital of Pittsburgh of UPMC in the Division of Pediatric Neurology. She is board certified in pediatrics, neurology, and psychiatry with Special Qualifications in Child Neurology. She is currently an Assistant Professor at the University of Pittsburgh School of Medicine. She began a multidisciplinary Mitochondrial Disease clinic in 2007 and is now the Director of Neurogenetics & Metabolism and the site Principle Investigator for NAMDC (the North American Mitochondrial Disease Consortium). She is also President of the Mitochondrial Medicine Society. Her clinical research interests include improving fatigue and exercise intolerance as well as developing common patient-centered outcome measures for clinical trials.
To view the accompanying slides, click here.
An update from Edison Pharma on the Development of EPI-743 clinical trial for children with Leigh Syndrome. Topics for this call include: Status on...
There is unprecedented momentum in the mitochondrial disease clinical trial landscape, and the patient community plays a vital role in ensuring these trials have...
Join MitoAction, Laura Pisani-Betancourt and Kristin Voorhees from Ultragenyx Pharmaceutical on Friday, July 9th, 2021 at 12:00pm EST for our monthly expert series presentation!...